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AML, there have been sparse reports regarding the outcome
of cord blood transplantation (CBT) for the population.
Patients and methods: We retrospectively reviewed
patients diagnosed as primary refractory AML who under-
went CBT at our institute from Mar. 2003 to June 2013
consecutively.
Results: Seventy-seven patients were included in this study.
Underlying diseases were de novo AML in 50 (65%) and AML-
MRC in 27 (35%). Forty-nine (61%) were male and 30 (39%)
were female. Their median age was 59 years (range 19-72).
The number of prior chemotherapy was 1 course in 28 (36%),
2 in 30 (39%), and more than 3 in 19 (25%), respectively.
Median time from diagnosis to transplantation was 162 days
(range; 64-1539). TBI+Cy/Bu+Cy was used as pretransplant
conditioning regimen in 4 patients, Flu+Mel80+TBI4 in 23,
Flu+Bu16+Mel80 in 26, Flu+Bu16+TBI2-4 in 12, and other RIC
regimens in 12. Nineteen patients died before engraftment.
Among the remaining 58 patients, 42 achieved neutrophil
engraftment with a median of 21 days post-transplant
(range; 13-45). Nine patients received urgent 2nd CBT for
primary graft failure (n¼6) or early disease relapse (n¼3).
Among the 42 evaluable patients, 36 (86%) developed acute
GVHD of grade II or higher, including 11 (26%) patients who
developed that of grade III or IV. Of the 36 patients who
survived longer than 100 days post-transplant, 21 patients
developed chronic GVHD, including 13 with limited and 8
with extensive form. With a median observation time for
survivors of 16.5 months (range; 3-94), 2 year overall sur-
vival (OS) and disease free survival (DFS) were 31.4% and
22.4%, respectively. Cumulative incidences of relapse and
non-relapse mortality (NRM) at 2 years post-transplant were
35% and 42.2%, respectively. In univariate analysis, patients
with aged 19-60 showed superior OS at 2 years compared to
elderly patients (>61 years) (44.8% vs 16.4% p¼0.013).
Relapse rate was signiﬁcantly higher in the elderly compared
to those with aged 19-60 (50.5% vs 21.7%, P<0.01), whereas
NRM did not differ between the two groups (43.3% vs 40.2%,
P¼0.87). Eighteen patients died of disease relapse and 36
died of NRM, including graft failure (3), infection (20),
bleeding (2), organ failure (4), TMA (3) and idiopathic
pneumonia syndrome (4).
Conclusion: Our results suggested that CBT is a feasible and
promising treatment approach for patients with primary
refractory AML. Optimal strategies for decreasing relapse
especially in the elderly should be established to improve the
outcome.219
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Introduction: Cytogenetic changes that accompany the
relapse of myeloid neoplasms after allogeneic hematopoietic
cell transplantation (HCT) have not been well studied. The
goal of our study is to evaluate the frequency and spectrum
of the cytogenetic change that occurs at relapse of myeloid
malignancies after HCT and evaluate the impact on
prognosis.
Methods: We performed a retrospective review of all pa-
tients who relapsed following an allogeneic HCT for a
myeloid malignancy. Cytogenetic ﬁndings at diagnosis and atrelapse were compared. Cytogenetic studies were performed
according to conventional methods.
Results: Of 212 patients transplanted for a myeloid malig-
nancy between 03/2004-01/2013, 43 relapsed (34AML,
1CML, 4MDS and 4MPN) at a median time of 113 days (range
22-820 days). Cytogenetic ﬁndings at relapse were different
from diagnosis in 14/43 patients (32.5%). The mean number
of cytogenetic alterations/patient increased from 1.09 at
diagnosis to 1.51 at relapse. The majority (10/14) represented
clonal evolution deﬁned as acquisition of more complex
abnormalities. This group includes 3 patients with normal
karyotype at diagnosis and 7 patients who originally showed
one, two, or complex abnormalities. All of these 10 patients
developed complex abnormalities (deﬁned as >3 abnor-
malities). Other than clonal evolution, new-onset chromo-
somal abnormalities unrelated to diagnosis were seen in
three patients, two of which acquired a more favorable
cytogenetic proﬁle than at diagnosis (inverted chromosome
16 and a single abnormality in a patient with complex
karyotype at diagnosis, respectively). One patient with
normal karyotype AML acquired a donor-derived del(20q)
abnormality.
Conclusions: Cytogenetic change is common at relapse of
myeloid neoplasms after HCT and is associated with an
increasing cytogenetic complexity. The acquisition of more
unfavorable cytogenetic proﬁles likely contributes to poor
outcomes. Exceptions to this trend are patients that acquire
more favorable cytogenetic features than at diagnosis,
resulting in potentially better response to therapy and longer
survival. The signiﬁcance of donor-cell-derived del(20q), a
rare recurrent cytogenetic abnormality in the post-trans-
plant setting, is not clear.220
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Abstracts / Biol Blood Marrow Transplant 20 (2014) S151eS164S156Acute Myeloid Leukemia (AML) not in remission at time of
HSCT carries a very poor prognosis. We previously reported
a single institution experience indicating signiﬁcant activity
for myeloablative clofarabine/busulfan conditioning
(CloBu4) in refractory hematologic malignancies, particularly
in AML (Blood. 2011 Oct 13; 118(15)). In an effort to better
establish efﬁcacy of HSCT with CloBu4 for AML not in
remission we initiated a multi-center phase II study with a
target accrual of 75 pts. Only pts with active AML deﬁned as
>5% myeloblasts on bone marrow examination within 14
days of registration were eligible. AML was required to be
refractory to two lines of intensive induction, one line of
induction following relapse (CR > 6 month), or untreated
relapse (CR < 6 months). Pts receiving previous HSCT were
excluded. Busulfanwas administered as a single daily dose of
3.2 mg/kg IV x 4d (days -5 to -2) targeting a plasma AUC of
4500-5500 mM.min/day and clofarabine as a single daily dose
of 40 mg/m2 IV x 5d (days -6 to -2). An 8/8 HLA matched
related or unrelated donor was required. GVHD prophylaxis
was per institutional preference, but included calcineurin
inhibitor together with either mycophenolate mofetil or
methotrexate. Twelve centers across US and Canada are
participating. At time of interim analysis there were 60 pts
with 56 evaluable for toxicity and response with additional
pt accrual expected at time of abstract submission. One pt
enrolled but withdrew before conditioning. Pts had median
age of 56 yrs (range: 3-65 yrs), received a median of 2 in-
ductions and had a median of 26% bone marrow blasts
(range: 5-94%) within 14 days of enrollment. Matched un-
related donors were utilized in 46% of pts. Pts engrafted at a
median of 13 days (range: 9-25) for neutrophils and 16 days
(range: 8-72) for platelets. The most frequent grade 3-4 non-
hematologic toxicities reported by day + 100 as related to
conditioning were infections (N¼6, 11%) and aGVHD (N¼4,
7%). Grade 5 non-hematologic toxicities possibly related to
conditioning include neutropenic enterocolitis (N¼1),
aGVHD (N¼1), pneumonia (N¼1), alveolar hemorrhage
(N¼1), ascites/veno-occlusive disease (N¼1), and metabolic
acidosis / sepsis (N¼1). Morphologic remissionwas observed
92% of pts with response assessment at day + 30 (N¼53). The
cumulative incidence of aGVHD grades II-IV by day + 100,
accounting for relapse and death as competing risks, was 37%
[95% CI: 24, 50]. Non-relapse mortality and relapse at one
year was 25% [95% CI: 11%, 38%] and 43% [95% CI: 27, 58],
respectively. The estimated one year OS and DFS are 39% [95%
CI: 24%, 64%] and 32% [95% CI: 20%, 52%], respectively. In
summary, preliminary analysis of a multi-center study of
CloBu4 conditioning in AML not in remission exhibits
impressive early responses with NRM and relapse incidence
similar to previous trials utilizing this regimen.221
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Disease relapse and graft-versus-host disease (GVHD) are the
major causes of treatment failure after allogeneic stem cell
transplantation (SCT). The DNA methyltransferase inhibitor
azacitidine (AZA) possesses signiﬁcant anti-tumor activity in
myelodysplasia and acute myeloid leukemia (AML). Recently
its administration post-transplant has been shown to both
induce a CD8+ T cell response to a broad range of tumor
antigens and augment reconstitution of T regulatory cells.
We therefore prospectively studied the impact of post-
transplant AZA on the outcome of patients allografted for
AML. 37 patients were transplanted using an alemtuzumab
based ﬂudarabine/melphalan conditioning regimen. 36 mg/
m2 of AZAwas administered for ﬁve consecutive days at four
weekly intervals until 12 months post-transplant. AZA was
commenced at a median of 54 days (range 40-194) post-
transplant and was well tolerated. 31 patients completed
three or more cycles. 16 patients relapsed at a median time of
8 months post-transplant. No patient developed chronic
extensive GVHD. AZA induced a CD8+ T cell response to tu-
mor-speciﬁc peptides in 16 of the 31 patients who received
more than three treatment cycles. No such response was
observed in matched controls who received no post-trans-
plant AZA. Induction of a CD8+ Tcell responsewas associated
with an increased one year overall survival of 81% versus 41%
in patients with no CD8+ T cell response (p¼ 0.02). An
increased number of T regulatory cells was detected in 16
patients compared with matched controls. In conclusion
administration of AZA post-transplant is associated with a
low incidence of GVHD and induces a CD8+ T cell response to
tumor antigens which correlates with a reduced risk of
relapse. These data demonstrate the ability of AZA to
improve the outcome of allogeneic SCT, potentially through
epigenetic manipulation of the alloreactive response, and
require validation in a randomised clinical trial.222
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Background: AML patients are frequently consolidated with
Allo-SCT in CR1. There is no consensus about the regimen
intensity (RIC versus ablative) in this setting.
